Compare PNR & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PNR | ILMN |
|---|---|---|
| Founded | 1966 | 1998 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.7B | 20.4B |
| IPO Year | 2003 | 2000 |
| Metric | PNR | ILMN |
|---|---|---|
| Price | $88.28 | $122.55 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 17 |
| Target Price | $116.62 | ★ $124.24 |
| AVG Volume (30 Days) | 1.3M | ★ 1.7M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.22% | N/A |
| EPS Growth | 5.88 | ★ 170.87 |
| EPS | 3.96 | ★ 5.45 |
| Revenue | N/A | ★ $4,343,000,000.00 |
| Revenue This Year | $4.21 | $6.52 |
| Revenue Next Year | $4.60 | $5.49 |
| P/E Ratio | ★ $22.29 | $22.49 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $74.25 | $68.70 |
| 52 Week High | $113.95 | $155.53 |
| Indicator | PNR | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 28.63 | 46.25 |
| Support Level | N/A | $114.88 |
| Resistance Level | $108.26 | $135.68 |
| Average True Range (ATR) | 2.48 | 4.25 |
| MACD | -0.60 | 0.03 |
| Stochastic Oscillator | 2.30 | 37.31 |
Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.2 billion in revenue in 2025.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.